Τρίτη, 2 Ιουλίου 2019

Complete response with neoadjuvant avelumab in Merkel cell carcinoma – A case report
Author links open overlay panelNadineAbdallahaMisakoNagasakabcTahmidaChowdhurybKunilRavaldJeffreyHotalingeAmmarSukarib
Department of Internal Medicine, Wayne State University, Detroit, MI, USA
Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
Department of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
Department of Pathology, Wayne State University, Detroit, MI, USA
Department of Otolaryngology Head and Neck Surgery, Wayne State University, Detroit, MI, USA
Received 26 June 2019, Accepted 28 June 2019, Available online 2 July 2019.

Show less rights and content
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin malignancy. We report here a case of localized MCC achieving pathologic complete response upon treatment with avelumab in the neoadjuvant setting. Preclinical and clinical studies have revealed a close relationship between MCC and the immune system, thus supporting a role for PD-1/PD-L1 inhibitors in MCC. This neoadjuvant use of PD-1/PD-L1 inhibitors can avoid potentially disfiguring surgery in MCC. As the incidence of MCC is rising, clinical trials are needed to evaluate the efficacy and safety of immunotherapy in resectable disease.

Merkel cell carcinomaAvelumabPD-1 inhibitorPD-L1 inhibitorNeoadjuvant
MCCMerkel cell carcinomaMCPyVMerkel cell polyoma virusNCCNnational comprehensive cancer networkORRobjective response rateOSoverall survivalPFSprogression-free survivalSEERsurveillance, epidemiology, and end results
View full text
© 2019 Published by Elsevier Ltd.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου